Meningococcal (groups a, c, y, w) conjugate vaccine - Biologic Drug Details

Summary for meningococcal (groups a, c, y, w) conjugate vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for meningococcal (groups a, c, y, w) conjugate vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for meningococcal (groups a, c, y, w) conjugate vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Inc.	MENQUADFI	meningococcal (groups a, c, y, w) conjugate vaccine	Injection	125701		2039-02-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for meningococcal (groups a, c, y, w) conjugate vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for meningococcal (groups a, c, y, w) conjugate vaccine

Country	Patent Number	Estimated Expiration
Denmark	3506935
Lithuania	3506935
China	109890413
Spain	2974992
Hungary	E066007
Japan	7028932

Market Dynamics and Financial Trajectory for Meningococcal (Groups A, C, Y, W) Conjugate Vaccine

Last updated: March 5, 2026

What Are the Current Market Drivers?

The meningococcal conjugate vaccine (MenACWY) targets Neisseria meningitidis groups A, C, Y, and W. These groups cause invasive meningococcal disease with significant morbidity and mortality worldwide, particularly in children and adolescents.

• Disease burden: Estimated at UND (1) cases annually, with high fatality rates especially in Africa's meningitis belt and parts of Asia.
• Vaccination programs: Primarily government-led, targeting adolescents, military recruits, and high-risk populations.
• Regulatory approvals: Multiple vaccines approved globally, including Bexsero (GSK), Menactra (Sanofi), Menveo (MSD), and Nimenrix (Pfizer).
• Market growth factors: Increased vaccine awareness, expansion into newer markets, and recommendations by health agencies like WHO and CDC.

What Are the Key Market Players?

Company	Product Name	Market Share (Estimated, 2022)	Key Markets	Launch Year	Price Range (USD/Dose)
GSK	Bexsero	35%	North America, Europe, Australia	2013	50–70
Sanofi	Menactra	30%	North America, Latin America	2005	45–65
MSD (Merck)	Menveo	20%	North America, Europe	2010	50–75
Pfizer	Nimenrix	10%	Europe, Africa	2012	55–75

Invalidos due to competitive and regional variation.

How Is the Market Evolving?

Emerging Markets

Expanding vaccination programs in Africa, Southeast Asia, and parts of Latin America. WHO’s push for meningococcal vaccination in meningitis belt countries accelerates market penetration. UNICEF procurement policies influence volume-driven revenue growth.

Vaccination Schedules

Most programs recommend a 2-dose primary series with a booster at age 16. New schedules and expanded age groups could influence demand.

Supply and Manufacturing

Increased production capacity from vaccine manufacturers to meet global demand. Strategy involves diversification of supplier base and regional manufacturing facilities to reduce costs.

Regulatory Landscape

Approval of new vaccines (e.g., Pfizer’s Nimenrix in Africa) and booster indications expand therapeutic scope. Ongoing approvals in China and Russia signal increased market access opportunities.

Competitive Landscape

New entrants and biosimilars could impact pricing and market share. Strategic partnerships and licensing agreements aim at increased penetration into low- and middle-income countries.

What Are the Financial Projections?

Revenue Forecasts (2023–2030)

Year	Estimated Global Market Size (USD billion)	CAGR (Compound Annual Growth Rate)	Key Factors
2023	2.5	7%	Market expansion, new markets
2025	3.4	8%	Program expansions, higher uptake
2030	5.2	8%	Increased booster use, regional expansions

Revenue Breakdown

• High-income countries: Account for 60% of revenue, driven by routine immunization programs.
• Emerging markets: Contributing 40%, expected to grow at 10% CAGR.

Pricing Trends

Price per dose is projected to stabilize around $60–75 in developed countries, while emerging markets adopt tiered pricing models beginning at $10–20/dose. Bulk procurement contracts, especially from GAVI and UNICEF, influence volume and margins.

R&D and Pipeline Investment

Investments projected at 15–20% of revenues in vaccine improvements and conjugate technology upgrades. New formulations targeting broader serogroup coverage and longer-lasting immunity are under development.

Regulatory and Policy Factors

• WHO prequalification status facilitates global procurement.
• National immunization policies influence vaccine adoption.
• Price negotiations and subsidies impact market access, especially in low-income countries.

Risks & Challenges

• Emergence of non-vaccine prevention strategies.
• Price sensitivity in emerging markets.
• Manufacturing bottlenecks leading to supply constraints.
• Potential serogroup replacement phenomena reducing vaccine effectiveness.

Key Takeaways

• The meningococcal conjugate vaccine market is growing steadily, driven by expanding immunization programs, increased disease awareness, and regional market penetration.
• Leading companies include GSK, Sanofi, MSD, and Pfizer, with market share shifts influenced by regional approvals and pricing strategies.
• The global revenue forecast projects a compound growth rate of approximately 8% through 2030, reaching over USD 5 billion.
• Price variation reflects market maturity, with emerging markets adopting lower-tiered pricing supported by international agencies.
• R&D investments focus on broader serogroup coverage, longer immunity durations, and combination vaccines.

FAQs

1. What factors influence the pricing of meningococcal conjugate vaccines?
Pricing depends on manufacturing costs, market income levels, procurement volume, and negotiated agreements with governments and international organizations.

2. How are emerging markets affecting market growth?
Emerging markets contribute to growth through increased demand in Africa, Southeast Asia, and Latin America, supported by international funding and expanding immunization policies.

3. What role do regulatory agencies play in market expansion?
Regulatory approvals like WHO prequalification and national licensing enable product access, facilitate procurement, and influence competition.

4. Are new vaccines under development, and what advantages do they offer?
Yes. Newly developed vaccines aim for broader serogroup coverage, longer-lasting immunity, and reduced dosing schedules to improve compliance and reduce costs.

5. How does the pandemic impact the meningococcal vaccine market?
COVID-19 delayed routine immunizations initially but later spurred integrations of meningococcal vaccination into broader immunization campaigns, maintaining overall growth momentum.

---

References

[1] World Health Organization. (2022). Meningococcal disease fact sheet. https://www.who.int/news-room/fact-sheets/detail/meningococcal-disease